Support teaching, research, and patient care.
Dr. Raffick Bowen is a Clinical Professor of Pathology and Co-Director of the Clinical Chemistry and Immunology Laboratory at Stanford University Medical Center. Dr. Bowen received his certification in Medical Laboratory Technology (MLT similar to MT/MLS/CLS in the United States) from the Canadian Society for Medical Laboratory Science (CSMLS) and has a license as a Clinical Chemist Specialist from the State of California. He completed his BSc in Medical Laboratory Science (MLS) and Ph.D. focusing on omega-6 and omega-3 fatty acids on brain neuronal and glial cell membrane structure and function with implications to the manufacturing of infant formula's fatty acid composition from the University of Alberta. Dr. Bowen completed a post-doctoral diploma in Clinical Chemistry (DClChem) from the University of Toronto and he became a Fellow of the Canadian Academy of Clinical Biochemistry (FCACB). Dr. Bowen has also spent a few years at the National Institutes of Health in Bethesda, Maryland as a Fogarty Post-Doctoral Fellow at the NIH Clinical Center. Dr. Bowen is a Diplomate of the American Board of Clinical Chemistry (DABCC). Also, Dr. Bowen is a Fellow of the American Academy of Clinical Biochemistry (FAACC). Dr. Bowen has also completed his Master in Health Administration (MHA) degree from the University of British Columbia. In summary, he is a Medical Technologist, Clinical Biochemist/Scientist with advanced business concepts as they relate to the healthcare system. I believe that philosophy dictates practice and engaging in this self-reflection process will result in an increased understanding of our beliefs about the nature of our professional work and life.As a leader, I believe in teamwork, collaboration, and collective decision-making. W. Edwards Deming is the main influence of my management philosophy: It is not enough to do your best; you must know what to do, and then do your best. I also believe that financial accountability, transparency, and continuous improvement are essential for the success of a diagnostic laboratory. " In God we trust; all others must bring data." - Dr. DemingMy vision of Laboratory Medicine is to provide a continuous quality of service that is beyond the expectations of our clients."Never regard study as a duty, but as the enviable opportunity to learn to know the liberating influence of beauty in the realm of the spirit for your own personal joy and to the profit of the community to which your later work belongs"Author: Albert Einstein
Blood collection tubes are much more complex devices than is commonly appreciated by clinical laboratorians. Commercial tubes have multiple components that contribute to the optimal formation of serum or plasma for laboratory analysis. My research has shown that the silicone surfactant, Silwet L-720, used in blood collection tubes from a major manufacturer interferes with some immunoassays. This surfactant causes desorption of capture antibodies from the solid-phase in some immunoassay reagents. In addition, these tube additives can interfere with other analytical techniques like mass spectrometry. Since the quality of patient care depends on the quality of all the information that a physician uses in making treatment decisions, blood collection tubes should be manufactured to an extremely high standard like other medical devices. These tube-related interferences unlike patient specimens are not detected by routine quality control or proficiency testing since laboratorians typically do not pour these materials into the tube types used by their lab. Thus, any tube-related interferences will be missed by the clinical lab, which can lead to increased costs due to recollection and retesting, misdiagnosis, erroneous test results, increased turnaround times of test results, delays in patient care, decreased patient satisfaction, and diminished reputation of a healthcare institution.I am currently testing different types of surfactants and tube wall surface modification on immunoassays. This work will hopefully lead to blood collection tubes with minimum or no assay interferences and a better understanding of the effects of blood collection tube surfactant and additives on clinical assays, particularly, immunoassays.